NVAXRegulatoryprnewswire

Novavax's Nuvaxovid™ 2025-2026 Formula COVID-19 Vaccine Approved in the U.S.

Sentiment:Positive (70)

Summary

Nuvaxovid™ is the only protein-based, non-mRNA COVID-19 vaccine available in the U.S. for the 2025-2026 vaccination season GAITHERSBURG, Md., Aug. 27, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the U.S. Food and Drug Administration has approved the Nuvaxovid™...

Original Article

Read the full article from the original source for complete details and context.

Read Full Article

Article published on August 27, 2025 by prnewswire